New Immunotherapy Drug Shows Promise for Advanced Prostate Cancer | Tumour Shrinkage in Trials

A new immunotherapy drug, VIR-5500, is showing remarkably positive results in early trials for men with advanced prostate cancer, offering a potential turning point in the treatment of a disease that often proves resistant to existing therapies. The findings, presented at the American Society of Clinical Oncology genitourinary cancers symposium in San Francisco, have been described as “stunning” by researchers involved in the study. Prostate cancer is the most commonly diagnosed cancer among men in many countries, with approximately 1.5 million new cases identified globally each year.

Understanding Immunotherapy and the ‘Immune-Cold’ Challenge

Immunotherapy represents a significant shift in cancer treatment, harnessing the body’s own immune system to fight the disease. Even as it has proven effective against several cancer types, prostate cancer has historically been demanding to treat with this approach. This is since prostate tumors are often described as “immune-cold,” meaning they don’t attract the attention of immune cells, making it hard for the body to mount an effective defense. VIR-5500 aims to overcome this challenge.

The drug works by acting as a T-cell engager – essentially a bridge between the body’s killer T-cells and the tumor cells that are attempting to evade detection. Professor Johann de Bono of the Institute of Cancer Research and the Royal Marsden NHS foundation trust, who led the work, explained that VIR-5500 is an engineered antibody designed to activate only within the tumor environment. This targeted activation is crucial, as other T-cell engagers have been linked to severe inflammatory responses in prostate cancer patients. The localized action also allows the drug to remain in the bloodstream for longer, potentially reducing the frequency of doses needed.

Phase One Trial Results: PSA Levels and Tumor Shrinkage

The phase one clinical trial, funded by Vir Biotechnology, involved 58 men with advanced prostate cancer who had stopped responding to other treatments. Researchers focused on two key indicators of treatment response: prostate-specific antigen (PSA) levels and tumor size. PSA is a biomarker; higher levels can indicate the presence of prostate cancer.

The trial employed a dose-escalation strategy, starting with low doses and gradually increasing them. Among the 17 men receiving the highest dose, a substantial proportion experienced significant reductions in PSA levels. Specifically, 82% saw their PSA levels fall by at least half, 53% experienced a decrease of at least 90%, and 29% saw a reduction of at least 99%. Perhaps even more encouragingly, five out of 11 patients with measurable tumors showed actual tumor shrinkage. In one particularly striking case, a 63-year-old man whose cancer had spread to his liver experienced the complete resolution of 14 cancerous lesions after six cycles of treatment.

Importantly, the majority of patients – 88% – reported only mild side effects, a significant advantage over some other immunotherapy approaches. This suggests VIR-5500 may offer a more tolerable treatment option for men with advanced prostate cancer. You can find more information about prostate cancer research at the American Cancer Society.

What Does This Imply for Patients? A Cautious Optimism

While these results are undeniably promising, it’s crucial to remember that this is a phase one trial. Phase one trials are primarily designed to assess safety and identify the optimal dosage of a new drug. They are not designed to definitively prove efficacy. Larger, phase two and phase three trials are needed to confirm these findings and determine whether VIR-5500 can truly improve outcomes for men with advanced prostate cancer.

Professor Charlotte Bevan of Imperial College London, who was not involved in the study, emphasized the potential excitement surrounding this advance in immunotherapy for prostate cancer, noting it could open up a new class of drugs. However, she also highlighted the importance of conducting studies with diverse patient populations, as disparities in prostate cancer outcomes exist across different ethnicities. This is a critical point, as ensuring equitable access to effective treatments is paramount.

The Role of T-Cell Engagers and Minimizing Side Effects

The success of VIR-5500 hinges on its ability to effectively engage T-cells without triggering excessive inflammation. T-cell engagers work by physically linking T-cells to cancer cells, prompting the T-cells to destroy the cancer cells. However, this process can sometimes lead to a “cytokine storm,” a dangerous overreaction of the immune system. The targeted activation of VIR-5500 within the tumor environment appears to mitigate this risk, offering a significant advantage over other T-cell engagers.

Looking Ahead: Further Trials and the Path to Approval

Researchers are now planning further clinical trials to build on these encouraging early results. Simon Grieveson, assistant director of research at Prostate Cancer UK, described the trial as “extremely promising” and underscored the urgent need for new and innovative treatments for prostate cancer, which claims the lives of over 12,000 men in the UK each year. The Guardian reports that Professor de Bono believes these results are “stunning” and could potentially lead to cures in the long term.

The next steps involve larger, randomized controlled trials, which will compare VIR-5500 to standard-of-care treatments. These trials will be crucial for determining whether the drug can significantly improve survival rates and quality of life for men with advanced prostate cancer. The process of bringing a new drug to market is lengthy and rigorous, involving multiple phases of clinical trials and regulatory review. However, the early data on VIR-5500 offer a beacon of hope for patients and researchers alike. The Institute of Cancer Research provides further information on their immunotherapy research.